Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Nephrocare Health IPO Date, Review, Price, Allotment Details

By Jagat Joshi
December 17, 2025

Nephrocare Health IPO open date is December 10, 2025 and the IPO will close on December 12, 2025. Nephrocare Health IPO is a Book Built Issue. The company to raise around ₹871.05 crores via IPO that comprises fresh issue of ₹353.40 crores and offer for sale up to 1,12,53,102 equity shares with face value of ₹2 each.

Nephrocare Health IPO price band is ₹438 to ₹460 per share. The retail quota is 35%, QIB is 50%, and HNI is 15%. Nephrocare Health IPO to list on BSE, NSE on December 17, 2025. The allotment of Nephrocare Health IPO date is December 15, 2025.

The company reported revenue of ₹769.92 crores in 2025 against ₹574.72 crores in 2024. The company reported profit of ₹67.10 crores in 2025 against profit of ₹35.13 crores in 2024. As per the financials the IPO investors should apply the IPO for a long term.

Nephrocare Health IPO Details

IPO Open Date	December 10, 2025
IPO Close Date	December 12, 2025
Face Value	₹2 Per Equity Share
IPO Price Band	₹438 to ₹460 Per Share
Issue Size	Approx ₹871.05 Crores
Fresh Issue	Approx ₹353.40 Crores
Offer for Sale:	Approx 1,12,53,102 Equity Shares
Issue Type	Book Built Issue
IPO Listing	BSE, NSE
DRHP Draft Prospectus
RHP Draft Prospectus

Nephrocare Health IPO Review & Key Points

Review: May Apply
Rating: 4

Nephrocare Health IPO Market Lot

The Nephrocare Health IPO minimum market lot is 32 shares with ₹14,720 application amount. The retail investors can apply up-to 13 lots with 416 shares of ₹1,91,360 amount.

Application	Lot Size	Shares	Amount
Retail Minimum	1	32	₹14,720
Retail Maximum	13	416	₹1,91,360
S-HNI Minimum	14	448	₹2,06,080
S-HNI Maximum	67	2,144	₹9,86,240
B-HNI Minimum	68	2,176	₹10,00,960

IPO Reservation

Investor Category	Share Offered	-% Shares
Anchor Investor	56,57,919 Shares	-%
QIB (Ex. Anchor)	– Shares	50%
NII Shares Offered	– Shares	15%
Retail Shares Offered	– Shares	35%

Nephrocare Health IPO Anchor Investors

Anchor Bidding Date	December 9, 2025
Anchor Investors List
Shares Offered	56,57,919 Shares
Anchor Size	260.26 Cr.
lock-in period end date 50% shares (30 Days)	January 14, 2026
lock-in period end date 50% shares (90 Days)	March 15, 2026

Nephrocare Health IPO Dates

The Nephrocare Health IPO date is December 10 and the close date is December 12. The Nephrocare Health IPO allotment will be finalized on December 15 and the IPO listing on December 17.

IPO Open Date:	December 10, 2025
IPO Close Date:	December 12, 2025
Basis of Allotment:	December 15, 2025
Refunds:	December 16, 2025
Credit to Demat Account:	December 16, 2025
IPO Listing Date:	December 17, 2025
IPO Bidding Cut-off Time:	December 12, 2025 – 5 PM

Promoters and Holding Pattern

The promoters of the company are Vikram Vuppala, Bessemer Venture Partners Trust, Edoras Investment Holdings Pte. Ltd., Healthcare Parent Limited, Investcorp Private Equity Fund Ii And Investcorp Growth Opportunity Fund.

Particular	Shares	% Share
Promoter Holding Pre Issue	9,26,50,799	78.90%
Promoter Holding Post Issue	10,03,33,516	71.49%

Objects of the Issue & Utilisation of proceeds

Purpose	Crores
Capital expenditure by the Company for opening new dialysis clinics in India and	₹129.11
Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by the Company	₹136
General corporate purposes	₹-

About Nephrocare Health IPO

Nephrocare Health Services Ltd. has been in the business of offering end-to-end dialysis care since 2010, with a large network of clinics across India and international markets. Diagnosis, haemodialysis, home and mobile dialysis, and wellness programs are among the services provided by Nephrocare, which also has its own pharmacy.

The company runs a total of 490 clinics, 447 in India and 43 across the Philippines, Uzbekistan, and Nepal as of March 31, 2025. Currently, the business is present in 269 towns in 21 Indian states and four union territories.

As of March 2025, the company had 5068 dialysis machines serving 29,281 patients and performing over 2.88 million dialysis sessions. Max, Fortis Escorts, Care Hospitals, Wockhardt, Paras, CMRI, Jehangir Hospital, and Ruby Hall Clinic are some of the major hospitals the company partnered with to run an in-house dialysis center.

Nephrocare Health IPO Company Financial Report

Amount ₹ in Crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹443.26	₹451.85	₹11.79	₹666.23
2024	₹574.72	₹541.56	₹35.13	₹806.02
2025	₹769.92	₹682.48	₹67.10	₹996.46
September 2025	₹483.97	₹456.07	₹14.23	₹1,193.68

Nephrocare Health IPO Valuation – FY2025

Check Nephrocare Health IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

KPI	Values
ROE:	13.45%
ROCE:	-%
EBITDA Margin:	22.05%
PAT Margin:	8.88%
Debt to equity ratio:	0.58
Earning Per Share (EPS):	₹8.28 (Basic)
Price/Earning P/E Ratio:	N/A
Return on Net Worth (RoNW):	13.19%
Net Asset Value (NAV):	₹59.56

Peer Group Comparison

Company	EPS	PE Ratio	RoNW %	NAV	Income
Narayana Health	38.90	50.62	NA	NA	5,482.98 Cr.
Jupiter Life Line Hospitals	29.47	51.27	14.27%	192.55	1,261.55 Cr.
Rainbow Children Hospital	23.97	64.00	16.56%	134.67	1,515.87 Cr.
Dr. Agarwal’s Healthcare	2.80	155.32	NA	NA	1,711 Cr.
Vijaya Diagnostics	13.95	73.20	NA	NA	681.39 Cr.
Dr. Lal Path Labs	58.48	50.75	22.30%	244.39	2,461.40 Cr.
Metropolis Healthcare	28.29	73.10	NA	NA	1,331.20 Cr.

IPO Lead Managers aka Merchant Bankers

ICICI Securities Ltd.
Ambit Pvt.Ltd.
IIFL Capital Services Ltd.
Nomura Financial Advisory & Securities (India) Pvt.Ltd.

Company Address

Nephrocare Health Services Ltd.
5 th Floor, D Block, iLabs Centre,
Plot 18, Software Units Layout,
Survey No. 64, Madhapur, Shaikpet,
Hyderabad, Telangana, 500081
Phone: +91 40 4240 8039
Email: cs@nephroplus.com
Website: http://www.nephroplus.com/

IPO Registrar

Kfin Technologies Ltd.
Phone: 04067162222, 04079611000
Email: nephrocare.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/

Nephrocare Health IPO FAQs

What is Nephrocare Health IPO?

Nephrocare Health IPO is Mainboard IPO. The company is going to raise ₹871.05 Crores via IPO. The issue is priced at ₹438 to ₹460 per equity share. The IPO is to be listed on BSE & NSE.

When Nephrocare Health IPO will open for subscription?

The IPO is to open on December 10, 2025 for QIB, NII, and Retail Investors. The IPO will close on December 12, 2025.

What is Nephrocare Health IPO Investors Portion?

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

How to Apply the Nephrocare Health IPO?

You can apply for Nephrocare Health IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

What is Nephrocare Health IPO Issue Size?

Nephrocare Health IPO issue size is ₹871.05 crores.

What is Nephrocare Health IPO Price Band?

Nephrocare Health IPO Price Band is ₹438 to ₹460.

What is Nephrocare Health IPO Lot Size?

The minimum bid is 32 Shares with ₹14,720 amount.

What is the Nephrocare Health IPO Allotment Date?

Nephrocare Health IPO allotment date is December 15, 2025.

What is the Nephrocare Health IPO Listing Date?

Nephrocare Health IPO listing date is December 17, 2025. The IPO is to list on BSE & NSE.

Note: The Nephrocare Health IPO price band and date are officially announced. The (Nephrocare Health IPO grey market premium) will be added to the IPO GMP page as it will start).

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.